Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
The evolving role of the optometrist in nonsurgical cataract management
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Clustered testing approach may identify fast-progressing glaucoma
  • Glaucoma

Clustered testing approach may identify fast-progressing glaucoma

Kelsey Moroz

A clustered testing methodology detected fast-progressing glaucoma, indicating a potential approach for assessing high-risk individuals.

The prospective Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study took place at the Bascom Palmer Eye Institute at the University of Miami and the Duke Eye Center at Duke University. A total of 126 eyes from 65 patients (mean age, 68 years) with open-angle glaucoma were assessed. Patients underwent 2 clusters of testing consisting of 5 weekly visits at baseline and again approximately 6 months later. Patients continued cluster testing every 6 months for a mean duration of 25 months (mean, 17 tests total). Each visit consisted of testing with standard automated perimetry (SAP) 24-2 and 10-2, and spectral-domain optical coherence tomography (SD-OCT).

A total of 19 eyes (15%) progressed based on SAP 24-2 MD over the 6-month period. Median rates of change for progressors and non-progressors were –2.70 dB/year and 0.02 dB/year, respectively (P<.001).

A total of 14 eyes (11%) progressed on SAP 10-2 MD, and 16 eyes (13%) progressed by retinal nerve fiber layer thickness, with 30 eyes (24%) progressing by function, structure, or both.

Of the 35 eyes that progressed during overall follow-up, 25 did so during the 6-month cluster period (sensitivity, 71%). Of the 90 eyes that did not progress during overall follow-up, 85 did not progress during the 6 months (specificity, 94%).

Of the 14 eyes considered fast progressors by SAP 24-2, SAP 10-2, or SD-OCT during overall follow-up, 13 were identified as progressing during the 6-month cluster period (sensitivity, 93%; specificity, 85%).

The study is limited by its relatively smaller sample size. In addition, the authors indicated that patients who agreed to undergo intensive testing may have been more inclined to participate if they thought their disease could be worsening.

“Our intensive clustered testing methodology offers promising implications for clinical trials investigating interventions to slow down glaucoma progression. It may also be of value for short-term assessment of high-risk subjects,” the authors concluded.

Reference

Medeiros FA, Malek DA, Tseng H, et al. Short-term detection of fast progressors in glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study. Ophthalmology. 2023;S0161-6420(23)00938-7. doi:10.1016/j.ophtha.2023.12.031

Share

Related Content

  • Glaucoma

Large wearable study examines physical activity and sleep in adults with glaucoma

  • Glaucoma

Optometrists expand role in glaucoma care worldwide, but barriers remain

  • Glaucoma

Global glaucoma disability rates decline despite rising case burden

  • Glaucoma

Adults with ASD show higher rates of glaucoma, cataract, and other eye conditions

  • Glaucoma

Cognitive function and comorbidity linked to different glaucoma medication adherence barriers

  • Glaucoma

AOA 2026: Surgical and technological advances to improve quality of life and reduce drop burden in glaucoma

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon